Compare HLI & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HLI | IMVT |
|---|---|---|
| Founded | 1972 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 8.5B |
| IPO Year | 2015 | 2019 |
| Metric | HLI | IMVT |
|---|---|---|
| Price | $129.05 | $44.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $194.29 | $33.00 |
| AVG Volume (30 Days) | 932.4K | ★ 1.0M |
| Earning Date | 05-06-2026 | 05-28-2026 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | ★ 6.87 | N/A |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $2,617,516,000.00 | N/A |
| Revenue This Year | $13.77 | N/A |
| Revenue Next Year | $12.10 | N/A |
| P/E Ratio | $111.36 | ★ N/A |
| Revenue Growth | ★ 9.55 | N/A |
| 52 Week Low | $112.83 | $14.47 |
| 52 Week High | $211.78 | $45.42 |
| Indicator | HLI | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 47.00 | 67.95 |
| Support Level | $112.83 | $37.16 |
| Resistance Level | $144.92 | N/A |
| Average True Range (ATR) | 4.40 | 1.47 |
| MACD | 0.47 | 0.34 |
| Stochastic Oscillator | 58.31 | 83.53 |
Houlihan Lokey Inc is an investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, valuation, and strategic consulting. The firm serves corporations, institutions, and governments world-wide with offices in the United States, Europe, and the Asia-Pacific region. The company operates in three segments. In the Corporate Finance business segment, it provides M&A and capital markets advisory services. Through the Financial Restructuring business segment, the company advises on some of the complex restructurings around the world. The Financial and Valuation Advisory Services business segment provides valuation and financial opinion, and financial and strategic consulting practices in the United States.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.